ORGANOGENESIS HOLDINGS INC. (ORGO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
25/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseORGO / S&P 2.53% / 15.20% |
LoseORGO / S&P 6.50% / 15.00% |
WinORGO / S&P 492.86% / 50.40% |
| 2026-Q11/3 |
LoseORGO / S&P -54.25% / -4.33% |
WinORGO / S&P 12.19% / 11.30% |
LoseORGO / S&P -5.88% / 27.70% |
| 2025-Q42/3 |
WinORGO / S&P 22.75% / 2.65% |
WinORGO / S&P 17.04% / 9.00% |
LoseORGO / S&P -650.00% / 13.40% |
| 2025-Q32/3 |
WinORGO / S&P 15.30% / 8.12% |
LoseORGO / S&P 2.24% / 4.61% |
WinORGO / S&P 100.00% / 13.45% |
| 2025-Q20/3 |
LoseORGO / S&P -15.28% / 10.94% |
LoseORGO / S&P -4.21% / 4.83% |
LoseORGO / S&P 7.69% / 10.63% |
| 2025-Q12/3 |
WinORGO / S&P 35.00% / -4.27% |
WinORGO / S&P 5.35% / 4.98% |
LoseORGO / S&P -525.00% / 10.57% |
| 2024-Q42/3 |
WinORGO / S&P 11.89% / 2.41% |
WinORGO / S&P 11.29% / 5.25% |
LoseORGO / S&P -150.00% / 6.15% |
| 2024-Q30/3 |
LoseORGO / S&P 2.14% / 5.89% |
LoseORGO / S&P 1.34% / 5.89% |
LoseORGO / S&P -160.00% / 6.11% |
| 2024-Q20/3 |
LoseORGO / S&P -1.41% / 4.28% |
LoseORGO / S&P -1.96% / 5.38% |
LoseORGO / S&P -262.50% / 5.12% |
| 2024-Q10/3 |
LoseORGO / S&P -30.56% / 10.56% |
LoseORGO / S&P -5.62% / 5.71% |
LoseORGO / S&P -63.64% / 5.59% |
| 2023-Q41/3 |
WinORGO / S&P 28.62% / 11.69% |
LoseORGO / S&P -3.94% / 6.81% |
LoseORGO / S&P -66.67% / 7.78% |
| 2023-Q30/3 |
LoseORGO / S&P -4.22% / -3.27% |
LoseORGO / S&P -3.07% / 7.52% |
LoseORGO / S&P -77.27% / -5.03% |
| 2023-Q21/3 |
WinORGO / S&P 55.87% / 8.74% |
LoseORGO / S&P -0.61% / 9.50% |
LoseORGO / S&P -84.91% / -8.57% |
| 2023-Q10/3 |
LoseORGO / S&P -20.82% / 7.50% |
LoseORGO / S&P -0.11% / 10.77% |
LoseORGO / S&P -81.97% / -15.69% |
| 2022-Q40/3 |
LoseORGO / S&P -16.98% / 7.56% |
LoseORGO / S&P -3.52% / 11.88% |
LoseORGO / S&P -82.61% / -17.99% |
| 2022-Q30/3 |
LoseORGO / S&P -33.61% / -4.88% |
LoseORGO / S&P 3.79% / 13.47% |
LoseORGO / S&P -6.38% / -1.41% |
| 2022-Q20/3 |
LoseORGO / S&P -35.96% / -16.10% |
LoseORGO / S&P 6.18% / 13.71% |
LoseORGO / S&P -7.02% / 11.04% |
| 2022-Q12/3 |
LoseORGO / S&P -17.53% / -4.60% |
WinORGO / S&P 21.84% / 15.97% |
WinORGO / S&P 64.86% / 42.23% |
| 2021-Q42/3 |
LoseORGO / S&P -35.11% / 11.03% |
WinORGO / S&P 38.15% / 15.00% |
WinORGO / S&P 392.86% / 96.40% |
| 2021-Q31/3 |
LoseORGO / S&P -14.32% / 0.58% |
WinORGO / S&P 45.79% / 10.77% |
LoseORGO / S&P -1275.00% / 69.42% |
| 2021-Q21/3 |
LoseORGO / S&P -8.78% / 8.55% |
WinORGO / S&P 60.74% / 6.58% |
LoseORGO / S&P -262.86% / 51.81% |
| 2021-Q12/3 |
WinORGO / S&P 141.97% / 6.17% |
WinORGO / S&P 42.75% / -1.06% |
LoseORGO / S&P ORGO unavailable / 7.39% |
| 2020-Q42/3 |
WinORGO / S&P 96.09% / 12.15% |
WinORGO / S&P 29.63% / -3.72% |
LoseORGO / S&P ORGO unavailable / -33.42% |
| 2020-Q30/3 |
LoseORGO / S&P 0.00% / 8.93% |
LoseORGO / S&P -19.39% / -2.04% |
LoseORGO / S&P ORGO unavailable / -27.10% |
| 2020-Q20/3 |
LoseORGO / S&P 18.89% / 20.54% |
LoseORGO / S&P -26.40% / -0.46% |
LoseORGO / S&P ORGO unavailable / -27.11% |
| 2020-Q10/3 |
LoseORGO / S&P -32.85% / -19.60% |
LoseORGO / S&P -22.99% / 3.47% |
LoseORGO / S&P ORGO unavailable / -14.75% |
| 2019-Q40/3 |
LoseORGO / S&P -26.79% / 9.07% |
LoseORGO / S&P -9.31% / 5.36% |
LoseORGO / S&P ORGO unavailable / 2.99% |
| 2019-Q31/3 |
LoseORGO / S&P -13.55% / 1.70% |
WinORGO / S&P 302.65% / 5.02% |
LoseORGO / S&P ORGO unavailable / 0.21% |
| 2019-Q20/3 |
LoseORGO / S&P 1.33% / 4.30% |
LoseORGO / S&P ORGO unavailable / 6.64% |
LoseORGO / S&P ORGO unavailable / 8.65% |
| 2019-Q10/3 |
LoseORGO / S&P -26.11% / 13.65% |
LoseORGO / S&P ORGO unavailable / 8.12% |
LoseORGO / S&P ORGO unavailable / 14.29% |
| 2018-Q41/3 |
WinORGO / S&P 0.20% / -13.52% |
LoseORGO / S&P ORGO unavailable / 9.05% |
LoseORGO / S&P ORGO unavailable / 18.23% |
| 2018-Q30/3 |
LoseORGO / S&P 1.00% / 7.71% |
LoseORGO / S&P ORGO unavailable / 10.21% |
LoseORGO / S&P ORGO unavailable / 19.06% |
| 2018-Q20/3 |
LoseORGO / S&P 0.30% / 3.43% |
LoseORGO / S&P ORGO unavailable / 9.03% |
LoseORGO / S&P ORGO unavailable / 14.46% |
| 2018-Q11/3 |
WinORGO / S&P 0.81% / -0.76% |
LoseORGO / S&P ORGO unavailable / 7.68% |
LoseORGO / S&P ORGO unavailable / 12.46% |
| 2017-Q40/3 |
LoseORGO / S&P -0.80% / 6.64% |
LoseORGO / S&P ORGO unavailable / 7.03% |
LoseORGO / S&P ORGO unavailable / 13.82% |
| 2017-Q30/3 |
LoseORGO / S&P 1.52% / 4.48% |
LoseORGO / S&P ORGO unavailable / 5.68% |
LoseORGO / S&P ORGO unavailable / 17.57% |
| 2017-Q20/3 |
LoseORGO / S&P -0.30% / 3.09% |
LoseORGO / S&P ORGO unavailable / 4.83% |
LoseORGO / S&P ORGO unavailable / 17.74% |
| 2017-Q10/3 |
LoseORGO / S&P ORGO unavailable / 6.07% |
LoseORGO / S&P ORGO unavailable / 3.67% |
LoseORGO / S&P ORGO unavailable / 13.32% |
| 2016-Q40/3 |
LoseORGO / S&P ORGO unavailable / 3.82% |
LoseORGO / S&P ORGO unavailable / 2.09% |
LoseORGO / S&P ORGO unavailable / 7.05% |
| 2016-Q30/3 |
LoseORGO / S&P ORGO unavailable / 3.85% |
LoseORGO / S&P ORGO unavailable / 0.20% |
LoseORGO / S&P ORGO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ORGO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -66.21% | 20.78% |
| Annualized return | -66.21% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ORGO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.76% | 83.14% |
| Annualized return | -36.61% | 12.86% |
10Y · 2017-01-05 to 2026-08-27
| Metric | ORGO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.15% | 319.30% |
| Annualized return | -15.83% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |